328 completed, 207 recruiting, 108 terminated, 83 unknown. 780 Phase 1, 205 Phase 2, 18 Early Phase 1, 10 Not applicable, 2 Phase 3.
Follow Advanced Solid Tumors: new trials by email Literature Review of Advanced Solid Tumors trials Research Report on Advanced Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CHO-A04 in Advanced Solid Tumors CHO-A04 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Cho Pharma Inc. | 62 | 2027-07-01 | 2026-10-22 |
| A Study of QLS5314 Monotherapy in Participants With Advanced Solid Tumors QLS5314 - Advanced Solid Tumors | Phase 1 | Not yet recruiting | Shanghai Qilu Pharmaceutical Research and Development Center LTD | 70 | 2027-01-26 | 2026-11-04 |
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | Not applicable | Not yet recruiting | Natera, Inc. | 920 | 2027-01-01 | 2026-10-27 |
| A Study of DXC016 in Patients With Advanced Solid Tumors. Cohort A: DXC016 dose escalation, Cohort B: DXC016 dose expansion - Advanced Solid Tumors | Phase 1 | Not yet recruiting | Hangzhou DAC Biotechnology Co., Ltd. | 170 | 2026-12-01 | 2026-11-12 |
| A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid Tumors SYH2051, Irinotecan Hydrochloride Liposome. - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 154 | 2026-11-30 | 2026-11-03 |
| Study of CM529D1 in Participants With Advanced Solid Tumors CM529D1 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Keymed Biosciences Co.Ltd | 128 | 2026-11-27 | 2026-10-23 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| A Study of BON-C1393 in Adults With Advanced Solid Tumors BON-C1393, Bevacizumab, Capecitabine - Solid Tumors, Advanced Solid Tumors | Phase 1 | Not yet recruiting | BeOne Medicines | 90 | 2026-11-23 | 2026-10-29 |
| A Clinical Trial to Evaluate the Safety and Tolerability of SYS6077 Injection in Participants With Advanced Malignant Tumor SYS6077 - Advanced Solid Tumors | Phase 1 | Not yet recruiting | Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd | 110 | 2026-11-22 | 2026-10-14 |
| A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002) MK-2750, 5-HT3 serotonin receptor antagonist, NK-1 receptor antagonist - Advanced Solid Tumors, Malignant Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 300 | 2026-11-16 | 2026-10-15 |
| A First-in-human Clinical Trial to Test if the Investigational Drug BNT3219 is Safe and Potentially Beneficial for People With Advanced Solid Tumors When Given Alone or Together With Other Investigational Drugs BNT3219 - Advanced Solid Tumors | Phase 1 | Not yet recruiting | BioNTech SE | 207 | 2026-11-01 | 2026-10-23 |
| A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn BNT3210 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | BioNTech SE | 173 | 2026-11-01 | 2026-10-21 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6062 in Patients With Advanced Solid Tumors. SYS6062 - Advanced Solid Tumors, Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 260 | 2026-11-01 | 2026-10-27 |
| A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) MK-2010, Pembrolizumab, 5-Fluorouracil - Malignant Neoplam, Advanced Solid Tumors | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 480 | 2026-10-21 | 2026-11-05 |
| A Study of DXC018 in Patients With Advanced Solid Tumors DXC018 - Advanced Solid Tumors | Phase 1 | Not yet recruiting | Hangzhou DAC Biotechnology Co., Ltd. | 110 | 2026-10-18 | 2026-09-30 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid Tumors SYS6043, bevacizumab, carboplatin - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 400 | 2026-10-15 | 2026-09-22 |
| A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors LCB02A - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | LigaChem Biosciences, Inc. | 191 | 2026-10-14 | 2026-10-19 |
| Phase I Study of SM2275 Injection in Patients With Advanced Solid Tumors SM2275 - Advanced Solid Tumors | Phase 1 | Recruiting | Beijing StarMab Biomed Technology Ltd | 72 | 2026-10-09 | 2026-11-05 |
| A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) MK-2010, Sacituzumab tirumotecan, Histamine H1 Receptor Antagonist - Advanced Solid Tumors, Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 200 | 2026-10-07 | 2026-10-15 |
| A Study of AK157D1 for Injection in Advanced Solid Tumors AK157D1 for injection - Advanced Solid Tumors | Phase 1 | Recruiting | Akeso | 243 | 2026-09-30 | 2026-10-13 |
Showing 20 of 848. Sign in to see all of them.
Neoplasms (112) · Carcinoma, Non-Small-Cell Lung (72) · Colorectal Neoplasms (65) · Breast Neoplasms (43) · Neoplasm Metastasis (41) · Ovarian Neoplasms (38) · Pancreatic Neoplasms (31) · Lymphoma (29) · Stomach Neoplasms (29) · Melanoma (28) · Squamous Cell Carcinoma of Head and Neck (28) · Triple Negative Breast Neoplasms (21) · Carcinoma, Renal Cell (17) · Endometrial Neoplasms (17) · Uterine Cervical Neoplasms (17)
Neoplasms (200) · Neoplasms by Site (183) · Neoplasms by Histologic Type (143) · Digestive System Diseases (109) · Digestive System Neoplasms (108) · Gastrointestinal Diseases (84) · Neoplasms, Glandular and Epithelial (84) · Respiratory Tract Diseases (82) · Respiratory Tract Neoplasms (82) · Lung Diseases (81) · Thoracic Neoplasms (81) · Gastrointestinal Neoplasms (80) · Skin Diseases (80) · Skin and Connective Tissue Diseases (80) · Bronchial Neoplasms (78)
pembrolizumab (42) · Carboplatin (37) · Injections (33) · Paclitaxel (28) · Bevacizumab (27) · Docetaxel (26) · Cisplatin (23) · Nivolumab (20) · Fluorouracil (17) · Gemcitabine (17) · Oxaliplatin (16) · Pemetrexed (15) · Capecitabine (14) · Cetuximab (14) · Leucovorin (14)
Novartis Pharmaceuticals (22) · Pfizer (20) · Bristol-Myers Squibb (19) · Amgen (17) · Merck Sharp & Dohme LLC (17) · Millennium Pharmaceuticals, Inc. (14) · Jiangsu HengRui Medicine Co., Ltd. (13) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (12) · AbbVie (11) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (11) · MedImmune LLC (11) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (11) · Astellas Pharma Global Development, Inc. (10) · AstraZeneca (9) · Qilu Pharmaceutical Co., Ltd. (9)
United States (403) · China (310) · Spain (105) · Australia (96) · South Korea (68) · Canada (66) · United Kingdom (65) · France (64) · Japan (56) · Italy (47) · Netherlands (38) · Taiwan (37) · Belgium (36) · Switzerland (36) · Germany (31)
Lin Shen (5) · Mark D. McKee, MD (4)
PMID 25749986, PMID 29158363, PMID 30120268, PMID 32816849, PMID 35596791, PMID 18729192, PMID 19900802, PMID 23429330, PMID 23591447, PMID 23903897, PMID 24241212, PMID 24252402, PMID 24487961, PMID 24563480, PMID 24737778, PMID 24810181, PMID 24898549, PMID 25043054, PMID 25113756, PMID 25253045, PMID 25260842, PMID 25377157, PMID 25403217, PMID 25761639, PMID 26073352, PMID 26084989, PMID 26155941, PMID 26179200, PMID 26655846, PMID 26689566, PMID 27251275, PMID 27329247, PMID 27372738, PMID 27764686, PMID 28158463, PMID 28222073, PMID 28665051, PMID 28817753, PMID 28932928, PMID 28939558, PMID 29037983, PMID 29059492, PMID 29510739, PMID 29551775, PMID 29563138, PMID 29603015, PMID 29660598, PMID 29954840, PMID 29980894, PMID 30018133
2023 (25), 2019 (11), 2016 (10), 2025 (10), 2015 (9), 2018 (8), 2009 (4), 2014 (3), 2008 (2), 2017 (2), 2004 (1), R21CA131820 (1), U01CA154967 (1)